|
End-of-day quote
Korea S.E.
2026-09-04
|
5-day change | 1st Jan Change | ||
| 21,600.00 KRW | +5.88% |
|
-17.08% | -49.18% |
| 06-08 | Alligator partner Henlius doses first patients in HLX22 study | FW |
| 05-22 | Alligator Bioscience comments on Henlius update for HLX22 | FW |
Company Valuation: AbClon Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 525,308 | 270,422 | 196,071 | 230,160 | 246,043 | 812,274 |
| Change | - | -48.52% | -27.49% | 17.39% | 6.9% | 230.14% |
| Enterprise Value (EV) 1 | 512,956 | 267,250 | 183,691 | 225,263 | 241,431 | 774,349 |
| Change | - | -47.9% | -31.27% | 22.63% | 7.18% | 220.73% |
| P/E | -81.6x | -26.4x | -21.2x | -17.4x | -14.5x | -43.5x |
| PBR | 19x | 14x | 5.45x | 8.66x | 8.49x | 14x |
| PEG | - | -0.5x | 2.17x | -0.4x | -1x | -686.68x |
| Capitalization / Revenue | 190x | 89.6x | 57.6x | 80x | 105x | 172x |
| EV / Revenue | 185x | 88.6x | 53.9x | 78.3x | 103x | 164x |
| EV / EBITDA | -94.2x | -30.3x | -25.4x | -22.6x | -17.2x | -46.2x |
| EV / EBIT | -78.1x | -26.1x | -21x | -19.3x | -15.5x | -43.3x |
| EV / FCF | -71.7x | -56x | -36.8x | -57.7x | -19.2x | -88.5x |
| FCF Yield | -1.4% | -1.79% | -2.72% | -1.73% | -5.21% | -1.13% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -447.3 | -670.1 | -604.5 | -849.6 | -975.4 | -976 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 2,771 | 3,018 | 3,406 | 2,877 | 2,340 | 4,714 |
| EBITDA 1 | -5,443 | -8,835 | -7,233 | -9,961 | -13,998 | -16,758 |
| EBIT 1 | -6,571 | -10,229 | -8,750 | -11,645 | -15,589 | -17,885 |
| Net income 1 | -6,445 | -10,238 | -9,254 | -12,904 | -16,302 | -17,907 |
| Net Debt 1 | -12,352 | -3,172 | -12,380 | -4,897 | -4,612 | -37,925 |
| Reference price 2 | 36,500.00 | 17,700.00 | 12,800.00 | 14,820.00 | 14,120.00 | 42,500.00 |
| Nbr of stocks (in thousands) | 14,392 | 15,278 | 15,318 | 15,530 | 17,425 | 19,112 |
| Announcement Date | 12/31/21 | 3/1/22 | 3/1/23 | 2/29/24 | 3/1/25 | 3/1/26 |
1KRW in Million2KRW
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 320M | |
| 19.17x | 4.48x | 10.55x | 0.47% | 82.65B | |
| 20.62x | 4.39x | 13.64x | 2.39% | 60.24B | |
| -17.31x | 25.92x | -17.11x | -.--% | 58.11B | |
| 35.25x | 12x | 23.01x | -.--% | 49.68B | |
| 21.03x | 4.65x | 13.26x | 0.69% | 46.66B | |
| 38.13x | 3.6x | 13.71x | -.--% | 32.63B | |
| 56.56x | 3.61x | 27.99x | -.--% | 25.69B | |
| 68.2x | 7.25x | 44.11x | -.--% | 22.73B | |
| 23.84x | 5.11x | 13.3x | -.--% | 16.54B | |
| Average | 29.50x | 7.89x | 15.83x | 0.39% | 39.53B | |
| Weighted average by Cap. | 23.28x | 8.64x | 12.28x | 0.54% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- A174900 Stock
- Valuation AbClon Inc.
Select your edition
All financial news and data tailored to specific country editions
